Here are relevant reports on : osteoarthritis-therapeutics-market
-
Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecasts to 2025
The global osteoarthritis therapeutics market growth is primed to transition from USD 7.3 billion in 2020 to USD 11.0 million by 2025, showcasing a strong CAGR of 8.7%.
- Published: December 2020
- Price: $ 4950
- TOC Available:
-
Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
The global exosome diagnostics and therapeutics market, valued at US$33 million in 2023, stood at US$59 million in 2024 and is projected to advance at a resilient CAGR of 81.2% from 2024 to 2032, culminating in a forecasted valuation of US$6,848 million by the end of the period. The growth of this market is driven by factors such as the increasing collaborations & commercialization initiatives, emerging potential of exosome-based liquid biopsy, and growing outsourcing of exosome manufacturing activities.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) & Region - Global Forecast to 2028
The global RNA therapeutics market, valued at US$32.2 billion in 2022, stood at US$13.7 billion in 2023 and is projected to advance at a resilient CAGR of 5.6% from 2023 to 2028, culminating in a forecasted valuation of US$18.0 billion by the end of the period. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Viscosupplementation Market by Product (Single, Three, Five Injection), Application (knee, hip osteoarthritis), Source (animal, non-animal), End-user (Hospitals, Orthopedic Clinics/ASCs), Region (northamerica, Asia Pacific, Europe) - Forecast to 2027
The global Viscosupplementation market size is projected to reach USD XX million by 2027 from USD XX million in 2022, at a CAGR of XX% during the forecast period. The market is driven by factors such as the increasing global prevalence of osteoarthritis, the increasing geriatric population, and the rise in sports injuries. On the other hand, the high cost of products is expected to limit market growth to a certain extent in the coming years.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Orthobiologics Market by Product (Viscosupplementation, Synthetic Orthobiologics, DBM, BMP, PRP, BMAC, Allograft), Application (Fracture Recovery, Osteoarthritis, Spinal Fusion, Soft Tissue), End User (Hospitals, ASCs, Academia) - Global Forecast to 2022
The global orthobiologics market is projected to reach USD 6.06 Billion by 2022 from USD 4.66 Billion in 2017, at a CAGR of 5.4% during the forecast period. Factors such as rising burden of orthopedic injuries; increasing incidence of sports injuries and road accidents; increasing incidence of spinal fusion surgeries; risk factors associated with increasing aging population, obesity rate, & high incidence of musculoskeletal disorders; and growing patient preference for minimally invasive procedures are driving the orthobiologics market. The major players in the market are DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, Harvest Technologies, Globus Medical, Orthofix International, RTI Surgical, K2M Group, Kuros Biosciences, Bioventus, NuVasive, SeaSpine, Arthrex, and Xtant Medical.
- Published: September 2017
- Price: $ 4950
- TOC Available:
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
RNAI Technology Market- by Application (Research, Therapeutics) - Global Forecasts to 2019
The report presents the latest advances in RNAi technologies and their clinical implication as a therapeutic platform. It charts the current trends in RNAi therapeutics, and analyzes the opportunities and challenges faced by the RNAi companies. The focus will be on the clinical needs, patented technologies and the competitive landscape across geographies.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
